#United States #New York #Class Action #Rocket Pharmaceuticals #RCKT

Class Action Lawsuit on Rocket Pharmaceuticals: Get Involved

In an important announcement, The Gross Law Firm is reaching out to investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) who experienced financial losses during a specified class period. If you purchased shares of RCKT between September 17, 2024, and May 26, 2025, you might be eligible to join a class action lawsuit that aims to recover your investment losses.

Understanding the Case

The allegations against Rocket Pharmaceuticals revolve around the company's misleading statements and omissions regarding the safety and clinical trial protocol of its drug, RP-A501. The complaint highlights the severe concerns that were kept from investors, including serious adverse events (SAEs) associated with the drug, which included the tragic death of a trial participant.

According to the submitted complaints, the management provided overly positive communications while omitting critical facts that would have affected investor decisions. Notably, Rocket modified the clinical trial's protocol to include a newly introduced immunomodulatory agent without adequately informing investors. By doing so, investors bought shares at inflated prices, unaware of the significant risks involved.

On May 27, 2025, the situation took a critical turn when Rocket announced that the FDA had placed a hold on the RP-A501 Phase 2 pivotal study due to these serious adverse events. This news triggered a 37% drop in Rocket’s stock price in just one day, plummeting from $6.27 to $2.33 per share. This drastic devaluation emphasized the repercussions of inadequate transparency from the pharmaceutical company.

Important Timeline

• - Class Period: September 17, 2024 - May 26, 2025
• - Deadline to Register as Lead Plaintiff: August 11, 2025

If you purchased shares during the identified timeframe, it is crucial to act quickly and register your participation in the class action suit. The Gross Law Firm is dedicated to ensuring that investors like you receive due compensation in light of the misleading practices that have occurred.

Next Steps for Shareholders

To join the class action lawsuit or to gain more information, shareholders should register through the provided link. Registrants will benefit from portfolio monitoring software that keeps them updated on the progress of their case. Importantly, becoming a lead plaintiff is not necessary to be part of the recovery efforts.

This opportunity may represent a significant way for investors to recoup losses and to hold Rocket Pharmaceuticals accountable for its actions. Joining the suit means you are standing up for your rights as an investor and contributing to ensuring corporate accountability in the healthcare sector.

Why Choose The Gross Law Firm?

The Gross Law Firm is a nationally acclaimed class action law firm known for its commitment to safeguard investors’ rights against misleading and illegal business practices. Their experience in cases like this represents an opportunity for collective recovery, ensuring that those who have suffered losses can see justice served. The firm upholds the principles of ethical conduct for corporations and champions responsible business practices.

For any inquiries or to get started on the registration process, you may contact The Gross Law Firm directly:
- Address: 15 West 38th Street, 12th Floor, New York, NY 10018
- Email: [email protected]
- Phone: (646) 453-8903

Remember, as an investor, knowing your rights and taking action can lead to recovery and reinforce the demand for transparency in the pharmaceutical industry.

Stay informed, register today, and be a part of the movement for accountability and recovery!